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Proton pump inhibitora b s t r a c t
Background: Acid suppressing drugs (ASD) are generally used in acute pancreatitis (AP); however, large
cohorts are not available to understand their efficiency and safety. Therefore, our aims were to evaluate
the association between the administration of ASDs, the outcome of AP, the frequency of gastrointestinal
(GI) bleeding and GI infection in patients with AP.
Methods: We initiated an international survey and performed retrospective data analysis on AP patients
hospitalized between January 2013 and December 2018.
Results: Data of 17,422 adult patients with AP were collected from 59 centers of 23 countries. We found
that 23.3% of patients received ASDs before and 86.6% during the course of AP. ASDs were prescribed to
57.6% of patients at discharge. ASD administration was associated with more severe AP and higher
mortality. GI bleeding was reported in 4.7% of patients, and it was associated with pancreatitis severity,
mortality and ASD therapy. Stool culture test was performed in 6.3% of the patients with 28.4% positive
results. Clostridium difficile was the cause of GI infection in 60.5% of cases. Among the patients with GI
infections, 28.9% received ASDs, whereas 24.1% were without any acid suppression treatment. GI infec-
tion was associated with more severe pancreatitis and higher mortality.
Conclusions: Although ASD therapy is widely used, it is unlikely to have beneficial effects either on the
outcome of AP or on the prevention of GI bleeding during AP. Therefore, ASD therapy should be sub-
stantially decreased in the therapeutic management of AP.
© 2020 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A. Demcsak et al. / Pancreatology 20 (2020) 1323e1331 1325Introduction Research Council in Hungary (TUKEB-22254-1/2012/EKU).Acute pancreatitis (AP) is an acute inflammatory condition of
the pancreas that can involve peripancreatic tissue or remote organ
systems. The global incidence of AP is 30e100 cases per 100,000
general population per year, and it is one of the most frequent
gastrointestinal (GI) causes of hospital admission [1]. Unfortu-
nately, research activity in the field is more underrepresented than
it should be [2]. Not surprisingly, there is no specific therapy
available for AP, symptomatic and curative treatments are based on
guidelines and the prior experience of the medical staff. Strikingly,
current AP guidelines do not include any information regarding the
administration of acid suppressing drugs (ASDs) such as proton
pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2-
RAs) in AP [3e6], despite the fact that ASDs are routinely admin-
istered in clinical practice in the majority of AP cases.
Conventionally, the management of AP patients included
nothing by mouth from the time of hospital admission. It was
believed that by doing so the inflamed pancreas can rest, because
fluid intake or solid nutrients would stimulate exocrine pancreatic
functions and promote the release of proteolytic enzymes. How-
ever, prior studies failed to support this idea and showed no benefit
from fasting or nasogastric suction [7,8]. In experimentally induced
pancreatitis, results showed that pantoprazole treatment reduced
tissue infiltration of inflammatory cells and acinar cell necrosis in
severe AP. They concluded that pantoprazole possesses anti-
inflammatory in vivo properties and attenuates the course of AP
[9]. During fasting for the protection of the upper GI mucosa and to
rest the inflamed pancreas, ASD administration could be a poten-
tially good therapeutic option. Patients with severe AP, especially
those who require intensive care treatment or mechanical venti-
lation are carrying a higher risk for stress-related acute gastric
mucosal lesions [10], which can lead to ulceration and GI hemor-
rhage. Protection of the gastric mucosa is a critical therapeutic goal
in a wide spectrum of gastric-acid-related diseases. H2-RAs and
PPIs are the cornerstones in the therapy of diseases inwhich gastric
acid has a causative primary or contributory role to prevent the
damage or propagate the healing of gastric mucosa. Nowadays, PPIs
are among the most commonly prescribed drugs with constantly
increasing usage, while several studies raising concerns regarding
their overprescription. Possible reasons for the continuous increase
in ASD use can be the empirical treatment of various GI symptoms
and prescriptions for inappropriate conditions [11e13].
There are contradictory results in the literature on the beneficial
and harmful effects of ASD administration in patients with AP
[14e17]. Such therapy might be beneficial if it decreases severity or
mortality; however, acid suppression can be harmful as it might
increase the risk for GI infections. Although many international
cohort studies were published in AP [18e20], few data are available
on the use of ASDs, GI bleeding, and infection. Therefore, our aims
were to understand the current global practice of ASD adminis-
tration in AP patients and to investigate the safety and efficacy of
these drugs in this patient population.
Materials and methods
Patients and data collection
To assess the worldwide trend of ASD administration in AP
patients, an invitation letter was sent out to the members of the
International Association of Pancreatology in January 2019 to
participate in the present study. The time period of data collection
was from January 2013 to December 2018. The study was approved
by the Scientific and Research Ethics Committee of the MedicalCenters had to provide data on the gender and age of the pa-
tient, severity of pancreatitis and mortality. In addition to the
general demographic data, they had to indicate whether the pa-
tients received ASDs (PPI or H2-RA) upon admission, during hos-
pitalization and at discharge irrespectively to its indication, timing,
dosing and form of administration. Centers had to include data on
the signs and cause of GI bleeding. It had to be recorded if a stool
culture test (SCT) was performed along with its result. In the case of
positive testing, the name of the pathogen had to be included.
Based on the data above, patients were assigned to two groups
depending on their ASD administration status during hospitaliza-
tion, onewhich received ASD treatment (group ‘ASD’) and the other
which did not (group ‘NoASD’). In the case of GI bleeding and GI
infection, the ASD treatment in the hospital was the indicator to
assign a patient to ‘ASD’ or ‘NoASD’ groups.Data quality
Datawere complete on age, gender, severity of AP andmortality,
in hospital ASD administration, registering the signs of GI bleeding,
and whether SCT was performed or not and its result. ASD
administration was unknown on admission in 1046 of the cases,
and in 10 patients at discharge. The cause of GI bleeding was un-
known in 5 patients.Diagnostic criteria
The diagnosis of AP was based on the IAP/APA evidence-based
guidelines for the management of AP A1 recommendation [3]. At
least two from the following three criteria should be confirmed in
patients: clinical (upper abdominal pain), laboratory (serum
amylase or lipase >3x upper limit of normal) and/or imaging (CT,
MRI, ultrasonography). Severity of pancreatitis was determined
based on the revised Atlanta classification [21]. This classification
defines three degrees of severity: mild, moderately severe (mod-
erate) and severe AP.
Signs of GI bleeding were provided by each center. These
included positive rectal digital examination, macroscopically
observed bleeding in the stool, vomit or gastric juice, positive stool
blood test, and bleeding verified by an imaging technique. We
excluded the bleeding cases that occurred in association with
endoscopic retrograde cholangio-pancreatography (ERCP) since
administration of ASDs does not have an effect on this type of
bleeding. If the cause of the GI bleeding could not be determined,
patients were not included in the analyses regarding GI bleeding.
The presence of pathogens in the stool verified by laboratory
testing was considered GI infections. Non-specific signs such as
fever, diarrhea and vomiting without testing were not accepted.
The pathogens were identified for each patient.Statistical analysis
To identify differences between categorical variables the Chi-
square with Fisher’s exact test was used. The significance level
was set at 0.05. Binary logistic regression with stepwise forward
elimination was used to observe independent prognostic factors
(age, gender, severity, ASD treatment, GI bleeding and infection) for
the main outcomes (ASD administration, GI bleeding and
infection).
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Characteristics of the cohort
Data of 17,422 adult patients with AP were collected retro-
spectively from 59 centers (Fig. 1, Supplementary Table 1). 9803 of
patients were male (56.3%) and 7619 were female (43.7%)
(Supplementary Figure A), the average age was 56.4 years
(Supplementary Figure B) in the cohort. In the studied population
10,490 (60.2%) of patients hadmild, 4508 (25.9%) hadmoderate and
2424 (13.9%) had severe AP (Supplementary Figure C). In total 4.6%
(800 patients) of patients died; the mortality rate was 0.4% (n¼ 44/
10,490) inmild,1.5% (n¼ 68/4508) inmoderate and 28.4% (n¼ 688/
2424) in severe AP (Supplementary Figure D). Upon admission,
23.3% of patients (n ¼ 3817/16,376) took some kind of ASD
(Supplementary Figure E). From these patients, 88.3% (n ¼ 3369/
3817) was admitted with a PPI, 11.3% (n ¼ 432/3817) with a H2-RA,
and 0.4% (n ¼ 16/3817) received both kind of ASD. During hospi-
talization, 86.6% of patients (n ¼ 15,096/17,422) received ASD
treatment (Supplementary Figure E), 81.8% (n ¼ 12,354/15,096) of
these patients had only PPIs, 15.4% (n ¼ 2331/15,096) had solely
H2-RAs and 2.7% (n¼ 411/15,096) had both PPIs and H2-RAs. At the
time of discharge from the hospital, 57.6% of patients (n ¼ 10,034/
17,412) were prescribed an ASD (Supplementary Figure E), 92.6%
(n ¼ 9293/10,034) of them received prescription for PPIs, 7.3% (n ¼
734/10,034) for H2-RAs and 0.1% (n ¼ 7/10,034) for both ASDs. For
the following parameters in the result section, only data during
hospitalization were analyzed.Acid suppression therapy is associated with more severe AP and
higher mortality
Patients were assigned to ‘ASD’ or ‘NoASD’ groups based on their
ASD administration status in the hospital. Among ‘ASD’ patients
mild AP (n ¼ 8649/15,096, 57.3%) was significantly less frequent
compared to those in the ‘NoASD’ group (n ¼ 1841/2326, 79.1%, p <
0.001). However, in case of moderate and severe pancreatitis, there
were significantly more patients in the ‘ASD’ group (moderate: n ¼
4139/15,096, 27.4%; severe: n ¼ 2308/15,096, 15.3%) than in the
‘NoASD’ group (moderate: n ¼ 369/2326, 15.9%, p < 0.001; severe:Fig. 1. Map of worldwide acid suppressing drug usage. Map shows the use of acin ¼ 116/2326, 5.0%, p < 0.001) (Fig. 2A). Mortality was significantly
higher in patients with acid suppressing therapy (n ¼ 744/15,096,
4.9%) compared to those without acid suppression (n ¼ 56/2326,
2.4%, p < 0.001) (Fig. 2B). Based on the results of logistic regression,
the patient’s gender did not influence the administration of ASD
treatment (OR ¼ 1.015, 95% CI ¼ 0.927e1.110, p ¼ 0.748); however,
older age (OR ¼ 1.006, 95% CI ¼ 1.003e1.008, p < 0.001) and worse
thanmild AP severity (OR¼ 2.202, 95% CI¼ 2.031e2.387, p < 0.001)
increased the patients’ chance for receiving ASDs during
hospitalization.Acid suppressing drug therapy is associated with higher risk for GI
bleeding in AP
Data for 17,282 patients were evaluated after excluding ERCP-
associated bleedings and bleedings of unknown origin. From
these patients, 817 (4.7%) had GI bleeding (Fig. 3A). The number of
patients having mild pancreatitis without GI bleeding was signifi-
cantly higher compared to those with GI bleeding (n ¼ 10,193/
16,465, 61.9% vs. n ¼ 221/817, 27.1%, p < 0.001, respectively).
However, among patients with GI bleeding there were significantly
more moderate (No bleeding: 4181/16,465, 25.4% vs. Bleeding: n ¼
283/817, 34.6%, p < 0.001) and severe AP (No bleeding: 2091/
16,465, 12.7% vs. Bleeding: n ¼ 313/817, 38.3%, p < 0.001) cases
(Fig. 3B). In case of GI bleeding, the rate of mortality was signifi-
cantly higher compared to patients without bleeding (No bleeding:
n ¼ 650/16,465, 3.9% vs. Bleeding: n ¼ 138/817, 16.9%, p < 0.001)
(Fig. 3B). There were significantly more patients suffering from GI
bleeding while receiving acid suppressing treatment compared to
those who did not (‘ASD’: n ¼ 766/14,975, 5.1% vs. ‘NoASD’: n ¼ 51/
2307, 2.2%, p < 0.001, respectively) (Fig. 3A).
The age (OR ¼ 0.998, 95% CI ¼ 0.992e1.005, p ¼ 0.585) and the
gender (OR ¼ 0.915, 95% CI ¼ 0.732e1.143, p ¼ 0.432) of patients
did not influence the chance of GI bleeding; however, worse AP
severity carried an almost 3 times higher probability of GI bleeding
(OR ¼ 2.994, 95% CI ¼ 2.623e3.418, p < 0.001). Furthermore, ASD
treatment during hospitalization increased the chance of GI
bleeding by 1.5-fold (OR ¼ 1.543, 95% CI ¼ 1.040e2.291, p ¼ 0.031),
and in case of verified GI infection the chance of GI bleeding was
almost 2.8 times higher (OR ¼ 2.789, 95% CI ¼ 1.997e3.894, p <d suppressing drugs in patients with acute pancreatitis during hospitalization.
Fig. 2. Disease severity and mortality rate in patients with or without acid suppressing drug (ASD) treatment. A) Disease severity in patients with (ASD) or without ASD (No
ASD) therapy. B) Number (n) and percentage of patients who received ASDs in the different severity groups, and mortality rates in ASD and No ASD groups.
A. Demcsak et al. / Pancreatology 20 (2020) 1323e1331 13270.001).Characterization of patients undergone SCT
From the 17,422 patients, an SCT was performed in 1102 cases
(6.3%) (Fig. 4A). There were significantly more patients with mild
AP who did not undergo stool culture testing (NoSCT: n ¼ 9961/
16,320, 61% vs. SCT: n ¼ 529/1102, 48%, p < 0.001). In case of
moderate and severe AP, the number of patients that underwent
testing during hospitalization was significantly higher (NoSCT: n ¼
4214/16,320, 25.8% vs. SCT: n ¼ 294/1102, 26.7%, p < 0.001 and
NoSCT: n ¼ 2145/16,320, 13.2% vs. SCT: n ¼ 279/1102, 25.3%, p <
0.001, respectively) (Fig. 4B). Mortality was significantly higher in
patients with stool culture testing (NoSCT: n ¼ 698/16,320, 4.3% vs.
SCT: n ¼ 102/1102, 9.3%, p < 0.001) (Fig. 4C). The frequency of SCT
orders increased with the severity of AP, mild: 5.0% (n ¼ 529/
10,490), moderate 6.5% (n ¼ 294/4508), severe: 11.5% (n ¼ 279/
2424). From the 1102 patients who underwent stool culture testing,
313 of them (28.4% of tested patients) had positive results. Themost
common pathogens causing GI infections were Clostridium difficile
(n ¼ 210/347, 60.5%) and the Klebsiella species (n ¼ 35/347, 10.1%)
(Supplementary Table 2A), and there was only a single pathogen
verified in 91.4% of the cases (n ¼ 286/313) (Supplementary
Table 2B).Acid suppressing treatment is not associated with higher risk for GI
infection
Among patients with GI infections, there was a significantly
lower number of patients in the mild AP group (n ¼ 95/313, 30.4%)
compared to the number of mild cases in patients without an
infection (n ¼ 434/789, 55%, p < 0.001) (Fig. 4D). We found
significantly more moderate (Positive: n ¼ 103/313, 32.9% vs.
Negative: n ¼ 191/789, 24.2%, p < 0.001) and severe (Positive: n ¼
115/313, 36.7% vs. Negative: n ¼ 164/789, 20.8%, p < 0.001) cases in
patients with positive SCT (Fig. 4D). In patients with GI infection,the mortality rate was significantly higher compared to the rate in
the group tested negative for GI infections (Positive: n ¼ 42/313,
13.4% vs. Negative: n ¼ 60/789, 7.6%, p ¼ 0.003) (Fig. 4E). GI
bleeding was significantly more frequent in patients with verified
GI infection (GI bleeding and GI infection: n ¼ 54/302, 17.9% vs. GI
bleeding without GI infection: n ¼ 81/770, 10.5%, p ¼ 0.001)
(Table 1). Therewas no significant difference in the occurrence of GI
infection between patients with or without ASD treatment (‘ASD’:
n ¼ 285/986, 28.9% vs. ‘NoASD’: n ¼ 28/116, 24.1%, p ¼ 0.276)
(Table 2).
Investigating the different factors that could have an effect on
the above results we found that the age (OR ¼ 0.999, 95% CI ¼
0.992e1.006, p ¼ 0.781) and the gender (OR ¼ 1.073, 95% CI ¼
0.847e1.359, p ¼ 0.559) of patients, and whether they received
ASDs or not (OR ¼ 1.447, 95% CI ¼ 0.969e2.161, p ¼ 0.071) did not
have an impact on the chance of having GI infection; however,
patients with worse than mild AP severity had a 2.5 times higher
odds for GI infections (OR ¼ 2.5, 95% CI ¼ 2.178e2.870, p < 0.001).Discussion
ASDs, especially PPIs are among the most frequently prescribed
drugs with increasing use every year. Even though there are well
established indications for a wide array of diseases when and how
to conduct treatment with ASDs, several studies were published
regarding their overprescription, and difficulties to discontinue
their application. Some suggests that possible reasons could be
prescription based on empirical decision or for conditions without
any indication [12,13,22,23]. Data from our cohort supports the
worldwide overuse of ASDs, specifically in patients with AP. 23.3%
of patients received ASD treatment before being admitted to the
hospital, and their number has increased by 3.7-fold during hos-
pitalization with almost all of the patients receiving some kind of
ASD. More than 50% of patients had remained on an ASD after
discharge, a more than 2-fold increase relative to the number at
admission. These numbers are in accordance with literature data
Fig. 3. Disease severity and mortality rate in patients with or without gastrointestinal (GI) bleeding. A) Percentage of patients with GI bleeding in the entire cohort, in patients
with or without acid suppressing drug (ASD) treatment. B) Disease severity in patients with and without GI bleeding. C) Number (n) and percentage of patients who had GI bleeding
or did not have GI bleeding in the different severity groups, and mortality rates.
A. Demcsak et al. / Pancreatology 20 (2020) 1323e13311328whereas patients after receiving ASDs during hospitalization get
usually discharged with them [23]. Unfortunately, this is another
example which shows that big difference can occur between
guidelines and their application [24]. Moreover, ASD treatment in
AP was associated with more severe pancreatitis and higher mor-
tality rate in our cohort.
There are contradictory results in the literature about the safety
of ASD use in AP. In a Korean randomized clinical trial, the in-
vestigators separated AP patients into two groups, one receiving
pantoprazole intravenously during fasting and later orally, and
another without PPI treatment. In this study, treatment with pan-
toprazole did not influence the clinical course of AP [14]. In another
randomized clinical trial from China, severe AP patients receiving
conventional therapy were compared to patients on conventional
therapy with esomeprazole treatment, and PPI therapy did not
show benefit on alleviating systemic inflammatory response and
improving clinical scores in severe AP patients, and did not prevent
the development of peptic ulcer and GI hemorrhage [15]. Data from
10,400 severe AP patients were analyzed in a Japanese retrospec-
tive study, and even though the rates of upper GI bleeding and
organ failure were significantly higher in patients with PPI therapy,
after propensity analysis, data showed that PPIs did not have an
effect on mortality [16]. On the contrary, in a Swedish population-
based case-control study, they observed association betweencurrent use of H2-RAs or PPIs and increased risk of AP, besides
previous literature data where they reported ASDs to cause AP [17].
Systemic inflammatory response syndrome is often a compli-
cation of severe AP, which leads to high level of inflammatory
markers [26] and organ dysfunctions. Patients with severe AP,
especially those who require intensive care treatment or mechan-
ical ventilation are prone to develop stress-related acute gastric
mucosal lesions [10]. Acute GI mucosal lesions can range from
simple gastritis and erosions to ulceration and bleeding [25], more
than half of patients with AP may develop upper GI ulcers, and the
occurrence shows positive correlation with the severity of
pancreatitis [8,27]. Hypersecretion of gastric acid seems to play a
major role at the pathogenesis of stress-related acute gastric
mucosal lesions. Therefore, in these cases it can be indicated to use
prophylaxis for peptic ulcer disease [8,28]. Based on our results, not
only in case of severe, but also in moderate pancreatitis cases there
were significantly more patients receiving ASD treatment which
supports our previous data about their frequent usage.
Protection of upper GI mucosa could be a possible indication for
ASD administration in AP patients, which could decrease the rate of
GI bleeding. Since ERCP- and surgery-related vascular complica-
tions cannot be prevented with ASD treatment, we did not include
these types of GI bleedings in our analyses. In the studied popula-
tion, 4.7% of patients suffered from GI bleeding. Although we did
Fig. 4. Disease severity and mortality rate in patients undergone stool culture testing (SCT). A) Percentage of patients who had SCT. BeC) Severity of acute pancreatitis and
mortality rate in tested and not tested patients. D-E) Severity and mortality in patients with or without gastrointestinal infection.
Table 1
Gastrointestinal (GI) infection in patients with or without GI bleeding. Results of
stool culture testing (SCT) in patients with or without GI bleeding with patient
number (n) and percentage.
No bleeding GI bleeding
n % n %
NEGATIVE SCT 689 89.5 81 10.5 770
POSITIVE SCT 248 82.1 54 17.9 302
Table 2
Gastrointestinal infection in patients with or without acid suppressing drug
(ASD) treatment. Result of stool culture testing (SCT) in patients with or without
ASD therapy with patient number (n) and percentage.
No ASD ASD
n % n %
NEGATIVE SCT 88 75.9 701 71.1
POSITIVE SCT 28 24.1 285 28.9
116 986
A. Demcsak et al. / Pancreatology 20 (2020) 1323e1331 1329not collect data on the cause of death, GI bleeding was associated
with higher morbidity and mortality, which increases the length
and cost of hospitalization. Investigating the association between
ASD treatment and GI bleeding, we found that bleeding occurred
more frequently in patients on ASD therapy which correlates with
literature data [15,16]. Based on the study of Chen et al. [8] inwhich
all the included patients received PPIs when a GI lesion wasdetected with endoscopy, 22% of severe pancreatitis patients had GI
bleeding [8].We did not collect data on the time of bleeding and the
start of ASD therapy. A possible explanation could be that when GI
bleeding was recognized then ASD therapy was started, although,
that still does not give an explanation why more than 80% of pa-
tients had to receive ASDs. Especially that more than 60% of pa-
tients had mild AP, and in that group only 2.1% of patients were
A. Demcsak et al. / Pancreatology 20 (2020) 1323e13311330suffering from GI bleeding. Therefore, these results suggest GI
bleeding recognition is not the indication of starting ASD treatment
in AP patients, and it also does not explain why more than 50% of
patients have to receive ASDs upon discharge from the hospital.
ASDs are considered well tolerated and effective, and only rare
and mild side effects have been reported in short-term use. How-
ever, nonessential long-term ASD treatment can lead to various
side effects in spite of their reported good safety profile [12]. Such
as elevated prevalence of small intestinal bacterial overgrowth
which results in malabsorption [29], increased risk for respiratory
infections [30,31] and several GI cancers (gastric, colorectal, liver or
pancreatic cancers) [13,31e35]. Other long-term side effects can be
micronutrient deficiencies, kidney disease, osteoporosis and de-
mentia. Long-term administration without proper re-evaluation
and guidelines will lead to polypharmacy and potential drug-
drug interactions [31]. Although several studies have shown asso-
ciation between adverse events and complications of long-term
ASD use, they have led to contradictory results [11]. Side effects
are also including elevated risk for GI infections by repressing the
gastric acid barrier and altering the microbiome. Notably, Clos-
tridium difficile infection has shown strong association with ASD
therapy [12,22,30,31,36,37]. From the wide array of possible long-
term complications, we investigated the relationship between
acid suppressing therapy and occurrence of GI infections in AP
patients. According to our results, ASD administration did not
elevate the risk for GI infections. However, ordering of SCTs has
been associated with more severe AP and higher mortality rate.
Even though, there was relatively low number of testing among the
included patients, almost 30% of them had GI infections. In our
cohort, the most common pathogen was Clostridium difficile (60%)
in accordance with literature data in other diseases. An important
factor that has to be taken into consideration is the frequent usage
of unnecessary antibiotic drugs in AP patients. The most frequently
used antibiotics can be effective for the most common GI infections
[38]. In the studied patient population, GI infections have been
associated with more severe AP, higher rate of GI bleeding and
worse mortality. Therefore, length of hospitalization and the cost of
treatment could be worse in patients with GI infections.
Our cohort analysis has its limitations, since it is a retrospective
data analysis, we cannot draw causative conclusions from the
findings above, only associations can be determined between the
investigated parameters.
Our aim was to investigate the current place of ASDs in patients
with AP and evaluate their safety and effectiveness that we could
present in a large AP population. Based on the epidemiologic
characteristics of our cohort and the numerous international cen-
ters who contributed data, our patient population substantiates a
general representation of patients with AP [39,40]. Our data shows
a worldwide unnecessary ASD use in AP patients, even though
there is no substantial evidence that ASD treatment is beneficial for
the therapy of AP. Hereby, we present their association with higher
morbidity and mortality. Our cohort analysis is among the first to
report data on the rate of GI bleeding not related to surgery or ERCP
in patients with AP. Based on our data, ASD administration during
AP did not increase the risk for GI infections. Taking into consid-
eration the advice from the American Gastroenterological Associ-
ation, the benefits of ASDs outweigh their risks if appropriately
prescribed, but when there is no indication, modest risks become
important because there is no potential benefit [15]. Therefore,
according to our results, the routine administration of ASDs is not
recommended in patients with AP if there is no other indication for
their administration. Long-term complications could be avoided by
re-evaluating the current clinical practices, incorporate recom-
mendations to current guidelines, and by giving detailed plans for
patients and their general practitioners how to gradually reduce orleave the ASDs, and when to follow up on them.
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